153 results
8-K
EX-99.1
BPTH
Bio-Path Holdings Inc
2 Apr 24
Bio-Path Holdings Provides 2024 Clinical and Operational Update
4:10pm
of 40 mg/m2.
Phase 1 Clinical Trial in BP1002 in Refractory/Relapsed Lymphoma and Chronic Lymphocytic Leukemia (CLL) – A Phase 1 clinical trial … to evaluate the ability of BP1002 to treat refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia (CLL) patients is currently
8-K
EX-99.1
BPTH
Bio-Path Holdings Inc
8 Mar 24
Bio-path Holdings Reports Full Year 2023 Financial Results
7:10am
of BP1002 in refractory/relapsed lymphoma and refractory/relapsed Chronic Lymphocytic Leukemia (CLL). As we look to the months and year ahead, we … BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients. In December, Bio-Path announced completion
8-K
rz1amlci2
10 Jan 24
Targeting Bcl-2 Protein Offers Potential Treatment for Patients Who Have Failed or Relapsed from Venetoclax-Based Frontline Therapy
4:10pm
8-K
EX-99.1
sjp02y aacctb398u4p
10 Jan 24
Targeting Bcl-2 Protein Offers Potential Treatment for Patients Who Have Failed or Relapsed from Venetoclax-Based Frontline Therapy
4:10pm
424B3
j7twcgr7
7 Aug 23
Prospectus supplement
7:21am
424B4
jty2qm7u
7 Aug 23
Prospectus supplement with pricing info
7:16am
424B5
hggt6ktp854
8 Nov 22
Prospectus supplement for primary offering
9:50pm